Replies to post #138080 on Biotech Values

[biotech jim]

I guess biotech deal price is going up.

At least for the percieved 'validated' mechanisms. Now I would not say that JAK(s) inhibitors are a validated mechanism for RA yet, but getting real close. Subtype complexity may not be an issue.

I suspect ABT management was asking the licensing and discovery groups where their JAK inhibitor was. On top of Humira, this is a pretty good bet on oral RA drugs IMO.

[pcrutch]

This is probably because Galapagos had a bit more clinical data than Incyte, no?

[mcbio]

It is a real large deal, especially compared to LLY's JAK1/2 RA deal with INCY two years ago. I guess biotech deal price is going up.

I assume the hefty premium is due in large part to the fact that the drug is entirely differentiated from the competition (JAK1-specific) and the hope that this will translate into a benefit. Quite a deal for Galapagos.